According to the 2019 Global Burden of Disease (GBD) study, the global prevalence of congenital heart disease (CHD) reached 13 million, with over 210,000 ...

Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...

Non-cystic fibrosis bronchiectasis (NCFB) is a heterogeneous disease characterised by a ‘vicious vortex’ of ...

Nerandomilast is an oral, preferential PDE4B inhibitor approved in China for the treatment of adult patients with IPF and PPF. It was also approved by the U.S. Food and Drug Administration (FDA) for ...

This study reports a valuable method to predict the capacity of a candidate probiotic bacterium to metabolically outcompete a bacterial pathogen in the ecological niche of the murine respiratory tract ...

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a rare lung condition, more life-threatening than many ...

Cereno Scientific will participate in meetings throughout the week and will also be present at the Biotech Showcase, an investor and partnering event, on January 12-14, running concurrently with J.P.

The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...

Introduction Asthma is a chronic respiratory disorder requiring ongoing medical management. This ecological study ...

Critical illness poses a significant global health challenge, disproportionately affecting low- and middle-income countries ...

Ad hoc announcement pursuant to Art. 53LRBASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- BV100 Phase 3 in Ventilator Associated ...

A male in his 50s presented to the renal department with a diagnostic challenge of an unexplained kidney injury.